Remission in depression: definition and initial treatment approaches

Journal of Psychopharmacology
Joshua A Israel

Abstract

Although remission is recognized as the optimal outcome of treatment for depression, remission lacks a universally accepted definition. This is partly due to the lack of objective biologic markers or tests that confirm a response to treatment and no well-defined end points of treatment. Significant symptoms may still exist even though patients may have a full response as measured by currently available standardized psychiatric rating scales. In addition, many patients may experience marked improvement in depressive symptoms but still have impaired psychosocial and work function. Wellness should be determined by evaluating a combination of three key domains: symptoms, functional status and pathophysiologic changes. In choosing an initial medication for depression, physicians are often guided by a mix of evidence-based medicine and unvalidated or even inaccurate clinical lore. In general, most available agents have comparable effectiveness; however, the subtype of depression and age of the patient should be considered.

References

Nov 1, 1995·Psychological Medicine·R RamanaP G Surtees
Nov 1, 1995·Psychological Medicine·E S PaykelA Barocka
Jun 1, 1996·The Psychiatric Clinics of North America·M Fava, K G Davidson
Apr 30, 1999·The Journal of Clinical Psychiatry·A A NierenbergM Fava
Jun 11, 1999·The Journal of Clinical Psychiatry·R M Hirschfeld
Nov 7, 2000·Biological Psychiatry·W C Drevets
Feb 21, 2002·Progress in Neuro-psychopharmacology & Biological Psychiatry·Timothy PetersenMaurizio Fava
Apr 2, 2003·The American Journal of Psychiatry·Frederic M QuitkinDonald Klein
Jun 19, 2003·JAMA : the Journal of the American Medical Association·Martin B Keller
Aug 13, 2003·Archives of General Psychiatry·Louis S MatzaJonathan W Stewart
Aug 5, 2004·The Journal of Clinical Psychiatry·Tarja K MelartinErkki T Isometsä
Oct 7, 2004·The American Journal of Psychiatry·Mark ZimmermanIwona Chelminski
Feb 25, 2005·The Journal of Nervous and Mental Disease·Heikki J RytsäläErkki T Isometsä
May 17, 2005·Journal of Affective Disorders·A John RushMadhukar H Trivedi
Jun 18, 2005·The Journal of Clinical Psychiatry·Frederic M QuitkinDonald F Klein

❮ Previous
Next ❯

Citations

Aug 3, 2010·Pharmaceuticals·Joshua A Israel
Dec 25, 2015·Current Medical Research and Opinion·Valerie WilliamsChristrophe Lançon
Aug 22, 2009·European Psychiatry : the Journal of the Association of European Psychiatrists·G BertschyG Bondolfi
Sep 17, 2014·Expert Opinion on Pharmacotherapy·William James Deardorff, George T Grossberg
Jun 16, 2011·The Annals of Pharmacotherapy·Wesley T Lindsey
Jul 31, 2009·Expert Opinion on Pharmacotherapy·William Victor Bobo, Richard C Shelton
Mar 26, 2009·International Clinical Psychopharmacology·Madhukar H TrivediEdward Kim
Oct 3, 2017·Current Treatment Options in Allergy·Ameya U AmritwarTeodor T Postolache
Mar 29, 2014·The Annals of Pharmacotherapy·Erica F Pearce, Julie A Murphy
Feb 27, 2016·Aggressive Behavior·Claire WilsonAllison McGowan

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.